TheracosBio

BRENZAVVY? (bexagliflozin) was listed as the lowest median cost among US currently approved noninsulin therapies in the 2025 ADA Guidelines.1 BRENZAVVY is a once-daily prescription pill approved by the FDA for use, along with diet and exercise, to lower blood sugar levels in adults with type 2 diabetes. ? With high out-of-pocket costs and financial burden on patients with type 2 diabetes leading to limited treatment and worsened outcomes,2 affordable treatment options can help alleviate the barriers to consistent diabetes management such as dosage skipping and prescription avoidance. ? BRENZAVVY is available for less than $50 per month through independent pharmacies and our online pharmacy partners, with or without the need for insurance or prior authorization. Important Safety Information: ? Do not take BRENZAVVY (bexagliflozin) if you: ? ? Are allergic to bexagliflozin or any ingredients in BRENZAVVY. ? BRENZAVVY can cause serious side effects, including: Diabetic ketoacidosis, lower limb amputation risks, dehydration, vaginal yeast infection, yeast infection of the penis (balanitis or balanoposthitis), serious urinary tract infections, low blood sugar (hypoglycemia), a rare but serious bacterial infection that causes damage to the tissue under the skin (necrotizing fasciitis) in the area between and around the anus and genitals (perineum), and serious allergic reaction. References: 1.???American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025. Diabetes Care 2025; 48 (Suppl. 1): S181-S206. 2.???Eberly LA, et al. Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US JAMA Netw Open. 2021;4(4):e216139. ? For important safety information and PI visit: https://brenzavvy.com/#isi

Disparities in diabetes care are real. According to the American Diabetes Association (ADA), race and financial status play a heavy role in determining who gets access to life-saving medications, technologies, and care. Systematic barriers to care include: 1 -?????Limited access to affordable medications -?????Fewer healthcare resources in underserved areas -?????Greater financial burden due to high out-of-pocket costs These barriers may lead to worsened health outcomes and higher complication rates. Reference: 1. Khedagi A, Hoke C, Kelsey M, et al. Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists.?Am J Prev Cardiol. 2023;13:100477. Published 2023 Feb 24. doi:10.1016/j.ajpc.2023.100477 #PatientCare #HealthcareAccess #DiabetesAwareness #SGLT2

In their 2025 Standards of Care in Diabetes, the American Diabetes Association (ADA) recommends health care teams discuss insurance coverage and financial barriers to care with all individuals with diabetes. When patients cannot afford expensive treatment options, they may skip doses or avoid filling prescriptions to save money, which can decrease treatment efficacy and lead to worse outcomes. BRENZAVVY? (bexagliflozin) is a once-daily prescription pill approved by the FDA for use, along with diet and exercise, to lower blood sugar levels in adults with type 2 diabetes. ? BRENZAVVY is available for less than $50 per month through independent pharmacies and our online pharmacy partners, with or without the need for insurance or prior authorization. Important Safety Information: ? Do not take BRENZAVVY (bexagliflozin) if you: ? ? Are allergic to bexagliflozin or any ingredients in BRENZAVVY. ? BRENZAVVY can cause serious side effects, including: Diabetic ketoacidosis, lower limb amputation risks, dehydration, vaginal yeast infection, yeast infection of the penis (balanitis or balanoposthitis), serious urinary tract infections, low blood sugar (hypoglycemia), a rare but serious bacterial infection that causes damage to the tissue under the skin (necrotizing fasciitis) in the area between and around the anus and genitals (perineum), and serious allergic reaction. For important safety information and PI visit: https://brenzavvy.com/#isi #PatientCare #HealthcareAccess #DiabetesAwareness #SGLT2

? When out-of-pocket costs stand in the way of diabetes care, the consequences can be life-threatening. The American Diabetes Association’s 2025 Standards of Care in Diabetes recommend minimal cost sharing for people with diabetes to help improve care. For many people living with diabetes, high out-of-pocket costs create barriers to accessing the medications and tools they need to manage their condition effectively. These barriers can include delayed care due to unaffordability, such as dosage skips, or avoidance of prescriptions. Unmanaged diabetes increases the risk of complications like heart disease and kidney failure, leading to worse outcomes for patients. ?? Minimal cost-sharing policies work. When patients have access to affordable medications and technologies—without the heavy financial burden—they’re more likely to: - Stick to their treatment plans - Achieve better blood sugar control - Maintain quality of life Treatment and positive outcomes for patients with diabetes should not be determined by their ability to pay. #DiabetesCare #AccessToCare #AffordableMedications #HealthcareEquity

? The American Diabetes Association has published its 2025 Standards of Care in Diabetes.1 In the section titled “Improving Care and Promoting Health in Populations”, factors that can influence treatment decisions, such as insurance coverage and formulary design, are discussed. Disparities in care arising from these factors significantly affect patients' access to life-saving medications and resources. Impact of Insurance Coverage: ?? High Out-of-Pocket Costs: Patients with high-deductible health plans often delay or skip necessary care, including refilling prescriptions for insulin or other medications like SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors. These delays can lead to poor blood sugar control. ?? Gaps in Coverage: Many insurance plans do not cover advanced diabetes technologies, such as continuous glucose monitors (CGMs) or insulin pumps. These tools are vital for optimizing glycemic control but are inaccessible to many due to cost barriers. ?? Medicaid Variability: Medicaid coverage varies widely between states, leading to geographic disparities. In non-expansion states, low-income individuals may fall into a coverage gap, leaving them uninsured and unable to afford diabetes care. Formulary Design Challenges: ?? Tiered Formulary Structures: Formularies often categorize medications into tiers, with lower-cost generics on Tier 1 and more expensive branded medications on higher tiers. Life-changing medications like SGLT2 inhibitors or GLP-1 receptor agonists may fall into high-cost tiers, placing them out of reach for many patients. ?? Step Therapy Requirements: Step therapy, also known as "fail first" protocols, requires patients to try and fail with less expensive medications before accessing more costly ones. This approach can delay effective treatment and adversely affect patient outcomes. ?? Exclusion of Certain Medications: Some formularies may exclude essential medications, ?forcing patients to pay the full price or go without them. For example, innovations in diabetes care, such as dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, are frequently excluded or have minimal coverage. Ensuring equitable access to medications and technologies can greatly enhance outcomes for individuals with diabetes, minimizing complications and improving their quality of life. #PatientCare #HealthcareAccess #DiabetesAwareness

Managing type 2 diabetes (T2D) often requires a combination of treatments to achieve optimal results. For many adults, metformin is the first-line medication to help lower blood sugar levels. However, when additional support is needed to reach hemoglobin A1c targets, combining treatments can make a significant difference. BRENZAVVY? (bexagliflozin), an FDA-approved medication, has been clinically proven to work effectively in combination with metformin (PI: https://lnkd.in/esYvUcVQ). Together, these medications can provide enhanced glucose control, helping to bring A1c levels into a healthier range. BRENZAVVY works by targeting blood sugar in a complementary way to metformin, offering a powerful tool for those who need more comprehensive management of their diabetes. While both medications are effective on their own, using them together as part of a tailored treatment plan can help address different aspects of type 2 diabetes. This approach supports better blood sugar stability and reduces the risk of complications of progression of disease over time. Of course, effective diabetes management is about more than just medications—it also involves a healthy diet, regular physical activity, and ongoing monitoring. For patients taking metformin who are still struggling to reach their A1C goals, combination therapy with BRENZAVVY may provide better results. With the right combination of therapies, patients can move closer to achieving the control they need for a healthy life. For important safety information and PI visit: https://brenzavvy.com/#isi #Diabetes #AffordableHealthcare #DiabetesAwareness

Type 2 diabetes mellitus (T2DM) affects a significant number of Americans. For individuals operating on a fixed budget, it may prove difficult to consistently afford medication for such diseases. BRENZAVVY? (bexagliflozin) is a once-daily prescription pill approved by the FDA for use, along with diet and exercise, to lower blood sugar levels in adults with type 2 diabetes. ? BRENZAVVY is available for less than $50 per month through independent pharmacies and our online pharmacy partners, with or without the need for insurance or prior authorization. For important safety information and PI visit: https://brenzavvy.com/#isi #Diabetes #AffordableHealthcare #DiabetesAwareness

The HHS IG found the federal gov't spends billions on type 2 diabetes meds. Elon Musk & Vivek Ramaswamy at DOGE & Mehmet Oz at CMS, why isn't the gov't buying #Brenzavvy? It's FDA-approved, up to?90% cheaper, &?has yet to have a price increase since its launch! #Brenzavvy #T2D Read Full Report: https://lnkd.in/e5WV3dV6

Type 2 diabetes is a condition that affects millions of people across the globe, but access to effective treatments isn't equitable. Medications like SGLT2 inhibitors (SGLT2-i) and GLP-1 receptor agonists (GLP1-RA) have been shown to improve blood sugar control and support overall health. Despite their potential to transform lives, these medications remain out of reach for many due to significant disparities based on income, race, and gender. The Cost Barrier: The high cost of medications is one of the primary obstacles to access. Monthly expenses for SGLT2 inhibitors range from $300 to $942, a price point that can be devastating for uninsured or underinsured individuals. For families already struggling with daily expenses, these life-saving medications often become an unaffordable luxury. The Role of Prior Authorizations: Even for those with insurance, the healthcare system presents additional hurdles. Prior authorizations, designed to control costs, often delay or deny access to these medications. This bureaucratic barrier disproportionately impacts marginalized communities, who may face challenges navigating the complex healthcare system or advocating for timely approvals. Income and Racial Disparities: Low-income individuals and communities of color often bear the brunt of these barriers. Studies show that Black, Hispanic, and Indigenous populations are less likely to be prescribed SGLT2-i and GLP1-RA medications compared to their White counterparts, even when clinically indicated?(https://lnkd.in/eudDiRTV). The reasons for this disparity are multifaceted, including implicit bias in healthcare, lower rates of insurance coverage, and limited access to specialty care. Gender Gaps in Treatment: Gender disparities also exist. Women with type 2 diabetes may be less likely to receive prescriptions for newer, innovative medications compared to men, potentially due to differences in how symptoms are reported or perceived by healthcare providers. Access to effective diabetes management shouldn’t depend on income, race, or gender—it’s a matter of health equity. Every person deserves the chance to live a healthier, longer life with the best tools available. #HealthEquity #Type2Diabetes #Diabetes #AffordableHealthcare

Managing type 2 diabetes involves more than just monitoring blood sugar levels; it’s about making choices that support overall health and well-being. BRENZAVVY? (bexagliflozin), an FDA-approved medication, has been studied in comparison to a widely used T2DM treatment (dapagliflozin). BRENZAVVY was found to be noninferior to dapagliflozin in providing glycemic control in patients with T2DM uncontrolled by metformin therapy alone. BRENZAVVY also provides equally effective decreases in body weight and systolic blood pressure to dapagliflozin. The occurrence of adverse reactions was also similar between the two treatment groups. Available for less than $50 per month through independent pharmacies and our online pharmacy partners, without the need for insurance or prior authorization, accessibility to BRENZAVVY helps patients get the care and treatment they need. For important safety information and PI visit: https://brenzavvy.com/#isi #Diabetes #AffordableHealthcare #DiabetesAwareness